keyword
https://read.qxmd.com/read/38556256/fusion-driven-cutaneous-and-superficial-mesenchymal-and-adnexal-tumors-a-clinicopathologic-and-molecular-study-of-15-cases-including-a-novel-case-of-actb-zmiz2-rearranged-adnexal-carcinoma
#1
JOURNAL ARTICLE
Carina A Dehner, Emma F Johnson, Carrie N Wieland, Michael J Camilleri, Andre Kajdacsy-Balla, Andre M Oliveira, Kevin C Halling, Sounak Gupta, Ruifeng Guo
BACKGROUND: While the list of fusion-driven soft tissue neoplasms is expanding rapidly, their importance among cutaneous and superficial mesenchymal and adnexal neoplasms remains poorly understood. This challenge is especially evident in cases with ambiguous histopathology that are difficult to classify based on morphology. AIMS: Our goal was to investigate the benefits of next-generation sequencing in diagnosing complex cutaneous neoplasms. MATERIALS & METHODS: Departmental archives were searched for fusion-driven cutaneous neoplasms...
March 31, 2024: Journal of Cutaneous Pathology
https://read.qxmd.com/read/38541753/the-functional-implications-of-transanal-irrigation-insights-from-pathophysiology-and-clinical-studies-of-neurogenic-bowel-dysfunction
#2
REVIEW
Gianna Rodriguez, Steven Kirshblum, Mai Thao, Mackenzie McArthur, Michael Camilleri
Defecation function is negatively impacted in patients with neurogenic bowel dysfunction (NBD), who require effective bowel care for stool evacuation. NBD comprises fecal incontinence and/or constipation, which can reduce the quality of life and dignity. Transanal irrigation (TAI) is recommended by several clinical guidelines as the second-line treatment after conservative treatment and before surgical options are considered. As the only class in the second-line treatment with an established safety and efficacy profile, the mechanism of action of TAI has not fully been elucidated when administered through a rectal catheter with a balloon...
March 7, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38533552/taar1-agonist-ulotaront-delays-gastric-emptying-of-solids-in-patients-with-schizophrenia-and-concurrent-metabolic-syndrome-with-prediabetes
#3
JOURNAL ARTICLE
Snežana Milanović, Nina Dedic, Robert Lew, Duane Burton, Kenneth S Koblan, Michael Camilleri, Seth C Hopkins
BACKGROUND: Metabolic syndrome (MetS), which can be induced or exacerbated by the current class of antipsychotic drugs, is highly prevalent in patients with schizophrenia and presents significant challenges to lifetime disease management. Supported by initial clinical results, trace amine-associated receptor 1 (TAAR1) agonists have emerged as potential novel treatments for schizophrenia. Notably, non-clinical studies have also shown weight-lowering and glucoregulatory effects of TAAR1 agonists, including the investigational agent ulotaront...
March 27, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38528940/risk-of-primary-gastrointestinal-lymphoma-in-patients-with-inflammatory-conditions-exposed-to-tumor-necrosis-factor-alpha-inhibitors-and-immunomodulators-a-case-control-study
#4
JOURNAL ARTICLE
Manuel B Braga-Neto, Jason Nasser, Xiao Xing Iris Wang, William Scott Harmsen, Laura E Raffals, Michael Camilleri, Victor Chedid
INTRODUCTION: The aim of this case-control study was to determine if exposure to tumor necrosis factor alpha inhibitors (TNFIs) or immunomodulators (thiopurines or methotrexate) was associated with development of primary gastrointestinal lymphoma (PGIL) in patients with chronic inflammatory conditions. METHODS: Patients with PGIL and controls evaluated at a tertiary care center over 20 years were matched 1:3 using a medical record informatics search engine based on their chronic inflammatory condition (Crohn's disease [CD], ulcerative colitis [UC], rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis) and duration of follow-up...
January 2024: Crohn's & colitis 360
https://read.qxmd.com/read/38456869/aga-clinical-practice-update-on-diagnosis-and-management-of-cannabinoid-hyperemesis-syndrome-commentary
#5
Alberto Rubio-Tapia, Richard McCallum, Michael Camilleri
DESCRIPTION: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update (CPU) is to review the available evidence and provide expert advice regarding diagnosis and management of cannabinoid hyperemesis syndrome. METHODS: This CPU was commissioned and approved by the AGA Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the CPUC and external peer review through standard procedures of Gastroenterology...
March 5, 2024: Gastroenterology
https://read.qxmd.com/read/38423684/characterization-and-management-of-amicrobial-pustulosis-of-the-folds-aseptic-abscess-syndrome-beh%C3%A3-et-disease-neutrophilic-eccrine-hidradenitis-and-pyostomatitis-vegetans-pyodermatitis-vegetans
#6
REVIEW
Giang Huong Nguyen, Michael J Camilleri, David A Wetter
Neutrophilic dermatoses are a broadly heterogeneous group of inflammatory skin disorders. This article reviews 5 conditions: amicrobial pustulosis of the folds, aseptic abscess syndrome, Behçet disease, neutrophilic eccrine hidradenitis, and pyostomatitis vegetans-pyodermatitis vegetans.The authors include up-to-date information about their epidemiology, pathogenesis, clinicopathologic features, diagnosis, and management.
April 2024: Dermatologic Clinics
https://read.qxmd.com/read/38237696/the-efficacy-of-tradipitant-in-patients-with-diabetic-and-idiopathic-gastroparesis-in-a-phase-3-randomized-placebo-controlled-clinical-trial
#7
JOURNAL ARTICLE
Jesse L Carlin, Christos Polymeropoulos, Michael Camilleri, Anthony Lembo, Michaela Fisher, Caleigh Kupersmith, Darby Madonick, Paula Moszczynski, Sandra Smieszek, Changfu Xiao, Gunther Birznieks, Mihael H Polymeropoulos
BACKGROUND: Neurokinin receptor 1 antagonists are effective in reducing nausea and vomiting in chemotherapy-induced emesis. We investigated the safety and efficacy of tradipitant, a neurokinin receptor 1 antagonist, in patients with idiopathic and diabetic gastroparesis. METHODS: A total of 201 adults with gastroparesis were randomly assigned to oral tradipitant 85 mg (n = 102) or placebo (n = 99) twice daily for 12 weeks. Symptoms were assessed by a daily symptom dairy, Gastroparesis Cardinal Symptom Index scores, and other patient-reported questionnaires...
January 17, 2024: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/38169126/review-article-pharmacologic-management-of-obesity-updates-on-approved-medications-indications-and-risks
#8
REVIEW
Camille Lupianez-Merly, Saam Dilmaghani, Kia Vosoughi, Michael Camilleri
BACKGROUND: Obesity has reached epidemic proportions, with >40% of the US population affected. Although traditionally managed by lifestyle modification, and less frequently by bariatric therapies, there are significant pharmacological advancements. AIMS: To conduct a narrative review of the neurohormonal and physiological understanding of weight gain and obesity, and the development, clinical testing, indications, expected clinical outcomes, and associated risks of current FDA-approved and upcoming anti-obesity medications (AOMs)...
February 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38086533/recent-developments-in-diagnosing-bile-acid-diarrhea
#9
REVIEW
Camille Lupianez-Merly, Saam Dilmaghani, Michael Camilleri
INTRODUCTION: Bile acid diarrhea (BAD) commonly causes chronic diarrhea. Symptoms may be mistaken for disorders of gut brain interaction. Due to the lack of widely available diagnostic tests and poor recognition of BAD, there is a delay in diagnosis leading to increased healthcare system burden and decreased patient quality of life. AREAS COVERED: A thorough review of the literature was conducted using PubMed for articles on the biological functions of bile acids, pathophysiology and management of BAD, but focusing on diagnostic testing including 75 SeHCAT retention, 7αC4, FGF-19, fecal bile acids, and single stool tests...
December 2023: Expert Review of Gastroenterology & Hepatology
https://read.qxmd.com/read/38085935/editorial-bile-acid-diarrhoea-simplified-clinico-biochemical-diagnosis
#10
EDITORIAL
Michael Camilleri
No abstract text is available yet for this article.
January 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38043694/low-incidence-of-pulmonary-aspiration-during-upper-endoscopy-in-patients-prescribed-a-glucagon-like-peptide-1-receptor-agonist
#11
JOURNAL ARTICLE
Diego Anazco, Sima Fansa, Maria Daniela Hurtado, Michael Camilleri, Andres Acosta
No abstract text is available yet for this article.
December 1, 2023: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/37993269/elobixibat-improves-rectal-sensation-in-patients-with-chronic-constipation-aged-%C3%A2-60-years-a-randomised-placebo-controlled-study
#12
RANDOMIZED CONTROLLED TRIAL
Noriaki Manabe, Minami Umeyama, Sonoko Ishizaki, Takumi Ota, Shinji Kuratani, Ryo Katsumata, Minoru Fujita, Ken Haruma, Michael Camilleri
OBJECTIVE: High rectal sensory thresholds (RSTs) are associated with chronic constipation (CC), especially in older patients. Bile acids (BAs) affect the RSTs of healthy individuals. Here, we aimed to investigate the effects of the BA transporter inhibitor elobixibat in patients with CC aged ≥60 years. DESIGN: We prospectively compared the RSTs of 17 patients with CC aged ≥60 years with those of 9 healthy individuals of the same age range. We next performed a prospective, randomised, parallel-group, double-blind, placebo-controlled clinical trial of 17 patients with CC who administered elobixibat or placebo daily for 1 week...
November 22, 2023: BMJ Open Gastroenterology
https://read.qxmd.com/read/37926943/neurohormonal-response-patterns-to-hunger-satiation-and-postprandial-fullness-in-normal-weight-anorexia-nervosa-and-obesity
#13
JOURNAL ARTICLE
Alejandro Campos, Tomas Marek, Gerardo Calderon, Wissam Ghusn, Lizeth Cifuentes, Leslie A Sim, Michael Camilleri, Barham Abu Dayyeh, John D Port, Andres Acosta
BACKGROUND: Food intake is regulated by homeostatic and hedonic systems that interact in a complex neuro-hormonal network. Dysregulation in energy intake can lead to obesity (OB) or anorexia nervosa (AN). However, little is known about the neurohormonal response patterns to food intake in normal weight (NW), OB, and AN. MATERIAL & METHODS: During an ad libitum nutrient drink (Ensure®) test (NDT), participants underwent three pseudo-continuous arterial spin labeling (pCASL) MRI scans...
November 5, 2023: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://read.qxmd.com/read/37917871/newer-pharmacological-interventions-directed-at-gut-hormones-for-obesity
#14
REVIEW
Michael Camilleri, Andres Acosta
The objective is to review the newer pharmacological interventions for obesity, specifically single, dual, and triple incretin receptor agonists that are either available or in the pipeline for treatment of obesity. The three incretin receptor targets are glucagon like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon. There are several approved single or dual incretin agonists which are administered subcutaneously daily (e.g., liraglutide) or weekly (e.g., semaglutide, dulaglutide, and exenatide QW), and experimental dual or triple incretin agonists...
November 2, 2023: British Journal of Pharmacology
https://read.qxmd.com/read/37814433/constipation-in-patients-with-chronic-kidney-disease
#15
REVIEW
Ra Ri Cha, Seon-Young Park, Michael Camilleri
Constipation is a frequent symptom in patients with chronic kidney disease (CKD). This review outlines the mechanisms and management of constipation in patients with CKD from a physician's perspective. Common causes of constipation in patients with CKD include concomitant medications, low dietary fiber intake, water-restricted diet, lack of physical activity, altered gut microbiota, and reduced gastrointestinal motility. Constipation has a negative impact on overall health, and, in particular, the presence of constipation has been associated with worsening kidney function and increased risk of developing advanced stages of CKD...
October 30, 2023: Journal of Neurogastroenterology and Motility
https://read.qxmd.com/read/37773554/intestinal-barrier-dysfunction-in-inflammatory-bowel-disease-underpinning-pathogenesis-and-therapeutics
#16
REVIEW
Katie A Dunleavy, Laura E Raffals, Michael Camilleri
The intestinal barrier is composed of several essential elements including luminal enzymes, bile acids, water layer, epithelial layer, and enterocyte layer. It acts as a dynamic interface between the luminal contents of food, commensal and pathogenic bacteria, and the gastrointestinal tract. The role of barrier dysfunction is of significant research interest in the development and targeted treatment of chronic inflammatory gastrointestinal conditions, such as inflammatory bowel disease. This review aims to examine the role of intestinal barrier dysfunction in the development of inflammatory bowel disease, the pathophysiology of increased barrier permeability in inflammatory bowel disease, and to explore potential treatment targets and clinical applications...
September 29, 2023: Digestive Diseases and Sciences
https://read.qxmd.com/read/37771793/new-developments-in-bile-acid-diarrhea
#17
JOURNAL ARTICLE
Michael Camilleri, Joelle BouSaba
Bile acid diarrhea (BAD) is characterized by increased frequency of bowel movements, looser stool consistency, urgency, and need for proximity to toilet facilities owing to the severity of the diarrhea, when compared with or relative to irritable bowel syndrome with diarrhea. Consequently, BAD leads to decreased quality of life. The condition is often misdiagnosed as irritable bowel syndrome with diarrhea or functional diarrhea. Patients with BAD have accelerated colonic transit, increased intestinal or colonic mucosal permeability, and altered stool microbiome composition associated with reduced dehydroxylation of primary to secondary bile acids...
September 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37753925/effects-of-glp-1-and-other-gut-hormone-receptors-on-the-gastrointestinal-tract-and-implications-in-clinical-practice
#18
JOURNAL ARTICLE
Michael Camilleri, Camille Lupianez-Merly
Agonists targeting the receptors of incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, have been well established for the treatment of type 2 diabetes mellitus. There is increasing awareness that gastroenterologists and hepatologists should be treating obesity when patients present to their clinics. In addition, gastroenterologists and hepatologists should be aware of the effects of these classes of medications prescribed by other providers. Therefore, given the widespread use of incretin agonists for obesity treatment and weight loss, it is important to recognize their effects in the gastrointestinal tract, which could constitute significant benefits in weight loss and cardiometabolic benefits, but can be associated with adverse effects that constitute a potential barrier to their use, particularly at higher doses...
October 19, 2023: American Journal of Gastroenterology
https://read.qxmd.com/read/37743018/beat-it-a-de-novo-cardiac-screening-program-in-maltese-adolescents
#19
JOURNAL ARTICLE
Mark Abela, Kentaro Yamagata, John Bonello, Sara Xuereb, Lisa Borg, Rachel Xuereb, Jeremy Fleri Soler, William Camilleri, Estelle Abela, Adrian Callus, Maria Farrugia, Karl Sapiano, Tiziana Felice, Melanie Burg, Mark A Sammut, Victor Grech, Michael Papadakis
AIMS: Sudden cardiac death (SCD) in young individuals is often unexpected, provoking substantial emotional stress for family and friends of the deceased. Cardiac screening may identify individuals who harbour disorders linked to SCD. The feasibility and diagnostic yield of a nationwide cardiac screening program in adolescents has never been explored. METHODS: All individuals eligible for cardiac screening (15-year old students) were systematically invited to enrol...
September 22, 2023: Hellenic Journal of Cardiology: HJC
https://read.qxmd.com/read/37726164/optimal-measurement-of-gastric-emptying-of-solids-in-gastroparesis-or-functional-dyspepsia-evidence-to-establish-standard-test
#20
JOURNAL ARTICLE
Michael Camilleri, Ting Zheng, Kia Vosoughi, Camille Lupianez-Merly, Deborah Eckert, Irene Busciglio, Duane Burton, Saam Dilmaghani
OBJECTIVE: Symptoms in gastroparesis (Gp) and functional dyspepsia (FD) overlap; using egg protein substitute to measure gastric emptying of solids (GES), ~40% of patients are reclassified from Gp to FD, and vice versa. Our aim was to assess inter-individual and intra-individual coefficients of variation (COV) in GES in symptomatic patients with Gp or FD with documented slow or normal GES, respectively. DESIGN: Scintigraphic GES (T1/2 and GE% at 2 and 4 hours) using a 320 kcal real egg meal (30% fat) was tested in the following: single measurements in 20 patients with diabetes mellitus (10 each type 1 and type 2); repeat GES to estimate COVintra measured: 3 days apart in 9 Gp, 4 weeks apart in 21 Gp and 18 with FD with normal GE assigned to placebo and in 70 patients at 94...
November 24, 2023: Gut
keyword
keyword
111043
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.